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Mast cell function and survival have been shown to be down-regulated under diabetic conditions. This
study investigates the role of the peroxisome proliferator-activated receptor (PPAR)-g in reducing mast
cell number and reactivity in diabetic rats. The effect of rosiglitazone on mast cell apoptosis was also
evaluated. Diabetes was induced by intravenous injection of alloxan into fasted rats and PPARg agonist
rosiglitazone and/or speciﬁc antagonist 2-chloro-5-nitrobenzanilide (GW9662) were administered
3 day after diabetes induction, once daily for 18 consecutive days. Mast cell apoptosis and plasma
corticosterone levels were evaluated by TUNEL and radioimmunoassay, respectively. Treatment with
rosiglitazone restored mast cell numbers in the pleural cavity and mesenteric tissue of diabetic rats.
Rosiglitazone also signiﬁcantly reversed the diabetes-induced reduction of histamine release by mast
cells, as measured by ﬂuorescence, following activation with the antigen in vitro. Increased apoptosis in
mast cells from diabetic rats were inhibited by rosiglitazone. Moreover, we noted that the increase in
plasma corticosterone levels in diabetic rats was inhibited by rosiglitazone. In addition, GW9662
blocked the ability of rosiglitazone to restore baseline numbers of mast cells and plasma corticosterone
in diabetic rats. In conclusion, our ﬁndings showed that rosiglitazone restored the number and
reactivity of mast cells in diabetic rats, accompanied with a suppression of apoptosis, in parallel with
impairment of diabetes hypercorticolism, indicating that PPARg has an important role in these
phenomena.
& 2012 Elsevier B .V .Open access under the Elsevier OA license.1. Introduction
Diabetes mellitus is a chronic metabolic disorder characterized
by absolute or relative deﬁciency in insulin secretion or action
and is associated with chronic hyperglycemia, which can cause
serious health complications including ketoacidosis, end stage
renal disease, heart disease, stroke, blindness and a variety of
debilitating neuropathies (van Belle et al., 2011). Among the
molecular causes of these complications, peroxisome prolifera-
tor-activated receptor (PPAR)-g has become a point of interest as
a ligand-activated nuclear transcription factor playing an impor-
tant role in maintaining glucose homeostasis by increasing insulin
sensitivity (Cho and Momose, 2008).
Several studies have alluded to the role of PPARg in type
1 diabetes by virtue of the reversal of disease progression
following treatment with selected PPARg agonists such asfax: þ55 21 2562 1357.
o).
lsevier OA license.rosiglitazone and troglitazona (Augstein et al., 2003; Awara
et al., 2005). Nevertheless, only sparse reports on the constitutive
expression and activation of PPARg are available in diabetes.
Studies have found that PPARg expression is decreased in the
vascular endothelium, renal cortex and retina of streptozotocin-
induced diabetic rats (Kanie et al., 2003; Wang et al., 2008) and in
adipose tissue and placenta from patients with gestational
Diabetes mellitus in comparison to patients with uncomplicated
pregnancies (Catalano et al., 2002; Holdsworth-Carson et al.,
2010). In inﬂammatory cells, PPARg was found to be signiﬁcantly
less expressed in the CD4þ and CD8þ lymphocytes of non-obese
diabetic mice, the well-established animal model for type 1 dia-
betes, in comparison to non-diabetic control mice (Yaacob et al.,
2009). The peritoneal macrophages from alloxan-diabetic rats had
a reduced PPARg expression which was involved in the produc-
tion of impaired reactive oxygen species when stimulated with
LPS (de Souza et al., 2007).
The prevalence of allergic diseases, such as asthma and atopic
dermatitis is decreased in patients with diabetes (Cakir et al.,
2008; Taleb et al., 2010). We previously reported that diabetic
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leakage in the pleural ﬂuid and skin, accompanied by a decrease
in the number of local mast cells (Carvalho V de et al., 2009;
Carvalho et al., 2006). In addition, the reconstitution of the mast
cell population in diabetic animals through adoptive transfer
system restored the allergic inﬂammation (de Oliveira Barreto
et al., 2003), suggesting that the down-regulation of mast cells
could be responsible at least in part for the lack of responsiveness
of diabetic animals to antigenic challenge. We have observed that
puriﬁed peritoneal mast cells from diabetic rats presented hypo-
responsiveness after immunological or non-immunological sti-
mulation in vitro, associated with an increase in the apoptotic rate
in these cells (Carvalho et al., 2011). Since mast cells express
PPARg and its activation increases mast cell differentiation and
proliferation (Maeyama et al., 2005), this study was undertaken to
evaluate the contribution of the PPARg in the reduction of mast
cell number and reactivity in diabetic rats using rosiglitazone
treatment.2. Materials and methods
2.1. Animals and diabetes induction
Male Wistar rats (180–200 g) were obtained from the Oswaldo
Cruz Foundation breeding colony and used in accordance with the
guidelines of the Committee on Use of Laboratory Animals of the
Oswaldo Cruz Foundation (CEUA-FIOCRUZ, license LW 23/11).
Diabetes was induced by administering a single intravenous (i.v.)
injection of alloxan monohydrate (40 mg/kg), diluted with sterile
saline (0.9% NaCl), into 12-h-fasted rats supplied with water ad
libitum. Animals injected with vehicle and submitted to similar
experimental conditions were used as negative controls. Blood
glycemia was determined by means of a glucose monitor (Johnson &
Johnson, California, USA) in samples obtained from the tail vein. After
alloxan injection, rats with blood glucose levels below 11mmol/l
were excluded from further experiments.2.2. Mast cell enumeration in the pleural ﬂuid
Twenty-one days after induction of alloxan-diabetes the ani-
mals were killed in a CO2 chamber, the thoracic cavity was
opened and rinsed with 3 ml heparinized saline (10 U/ml). The
pleural ﬂuid volume was measured in a graduated syringe. Mast
cells were counted in Neubauer chamber after dilution of pleural
ﬂuid samples (90 ml) with toluidine blue dye solution (10 ml).
Results were expressed as total mast cells 103 per cavity.2.3. Mast cell enumeration in the mesentery
The animals were injected intraperitoneally (i.p.), after death,
with 5 ml of paraformaldehyde (4%) diluted with a sucrose
solution (4%). After 15 min, the peritoneal cavity was opened;
the mesentery was recovered and placed on glass slides to dry at
room temperature. The mast cell population was identiﬁed in the
mesenteric membrane after staining with Giemsa dye (de Oliveira
Barreto et al., 2003). The number of mast cells was counted by
means of an optical microscope (Olympus BX50), which was
coupled to a video camera (Olympus, UC30). The camera output
was processed and analyzed by image analyzer software (Image-
Pro Plus 6.2). The number of mast cells was expressed per square
millimeter, and at least 16 ﬁelds (each 1 mm2) per mesentery
were examined.2.4. Mast cell puriﬁcation and stimulation
Mast cells were recovered from the peritoneal cavity and
puriﬁed by means of continuous Percoll gradient (de Oliveira
Barreto et al., 2003). After peritoneal washing with heparinized
(10 U/ml) calcium and magnesium-free HBSS (HBSS–), the cells
were centrifuged at 150 g for 10 min, the supernatant was
discarded and the pellet resuspended in HBSS– containing 0.1%
BSA. The cell suspension was mixed with Percoll (90%) and
overlaid with 1 ml of HBSS– to be further centrifuged at 150 g
for 25 min. Pelleted mast cells were washed twice with HBSS– and
purity was over 96% as shown by toluidine blue staining. Viability,
tested by Trypan blue exclusion, was higher than 95%. Isolated
mast cells (1105 cells/ml) were sensitized with IgE anti-DNP
antibody (0.5 mg/ml) at 37 1C for 1 h and, then, stimulated with
antigen (DNP-BSA, 0.5 mg/ml) for 1 h at 37 1C in 5% CO2 in air.
After centrifugation at 150 g for 10 min, the supernatant was
collected and stored at –20 1C for histamine quantiﬁcation
according to Shore et al. (1959). This method consists of sample
dilution in 0.1 N HCl followed by 0.8 N of NaOH, and further
addition of the substrate o-phthaldialdehyde. After 4 min of
incubation, the reaction was stopped with 3 N HCl and the
ﬂuorescence was measured in a Shimadzu RF1501 spectroﬂuor-
ophotometer (Kyoto, Japan; excitation at 360 nm; emission at
450 nm).
2.5. Detection of apoptosis
Total cells were recovered from the peritoneal cavity and ﬁxed
with formaldehyde (4%) for apoptosis assessment using a horse-
radish peroxidase-labeled streptavidin (streptavidin-HRP) TUNEL
assay (Roche Applied Science, Indianapolis, USA) performed
according to the manufacturer’s instructions. Fragmented DNA
in the nucleus was detected through biotinylated nucleotides
binding in the DNA 30–OH ends using natural or recombinant
terminal deoxynucleotidyl transferase (TdT or rTdT). The cells
were stained with toluidine blue dye to identify mast cells. Then,
the number of apoptotic mast cells was counted by means of an
optical microscope (Olympus BX50), which was coupled to a
video camera (Olympus UC30). The camera output was processed
and analyzed by image analyzer software (Image-Pro Plus 6.2).
The proportion of apoptotic mast cells was expressed in percen-
tage of positive mast cell count for TUNEL.
2.6. 15-Deoxy-D12,14-PGJ2 (15d-PGJ2) evaluation
Enzyme immunoassay (EIA) was used to measure 15d-PGJ2 in
plasma and mesentery homogenates tissue. Blood was collected
from the abdominal aorta with heparinized (400 U/ml) saline and
centrifuged for 10 min at 1,000 g, and the plasma was stored at
–80 1C until use. Mesentery was homogenized on ice in assay
buffer (1 ml/50 mg of lung tissue) and centrifuged for 15 min at
12,000 g, and the supernatant was stored at –80 1C until use. EIA
for 15d-PGJ2 was carried out using a Correlate-EIA kit (Assay
Designs Inc., Michigan, USA) according to the manufacturer’s
instructions. The cross-reactivity of this EIA kit for a number of
eicosanoids was determined by the manufacturer. The competi-
tive 15d-PGJ2 EIA analysis exhibits cross-reactivity with PGJ2
(49.0%), D12-PGJ2 (5.9%) and PGD2 (4.9%). Color intensity was
measured at 405 nm using a microplate reader, SpectraMax M5
(Molecular Devices, California, USA).
2.7. Hormones evaluation
21 day after alloxan-diabetes induction, blood was collected
from the abdominal aorta with heparinized (400 U/ml) saline and
500
400
150
Non-diabetic
Diabetic
200
300
100
15
-D
eo
x
y-
Δ1
2,
14
-
PG
J 2
 
(ρ
g)/
m
g 
o
f t
is
su
e
0
100 +
15
-D
eo
x
y-
Δ1
2,
14
-
 
PG
J 2
(ρ
g/
m
L)
0
50
+
Fig. 1. Effect of diabetes on plasma (A) and mesenteric (B) levels of 15d-PGJ2. The analyses were made 21 day after diabetes induction with alloxan (40 mg/kg). Data are
expressed as mean7S.E.M. of 6 animals. þPo0.05 compared to non-diabetic rats.
Table 1
Effect of treatment with rosiglitazone on blood glucose, glycated albumin, body
weight and plasma insulin levels in alloxan diabetic rats.
Group Drug Glycaemia Fructosamine Body Plasma insulin
R.C. Torres et al. / European Journal of Pharmacology 691 (2012) 261–267 263centrifuged for 10 min at 1,000 g, and the plasma was stored
at -20 1C until use. Plasma levels of insulin and corticosterone
were evaluated by means of radioimmunoassay (MP Biomedicals,
Solon, OH, USA) following manufacturer’s guidelines.(mmol/l) (mmol/l) weight (g) (mU/ml)
Non-
diabetic
 570.2 406718 318710 1871
þ 570.4 468713 32673 n.e.
Diabetic  3070.8a 560746a 210710a 771a
þ 2570.7b 566732 19472 871
Diabetic rats were treated with rosiglitazone (0.5 mg/kg, i.p.) and the analyses
performed 21 days after diabetes induction. Untreated animals received an equal
amount of vehicle (DMSO 0.05%, i.p.). Values represent mean7S.E.M. of 6 animals.
(n.e.¼ not evaluated).2.8. Fructosamine quantiﬁcation
Blood was collected from the abdominal aorta with hepari-
nized (400 U/ml) saline and centrifuged for 10 min at 1,000 g,
and the plasma was recovered for assessment of fructosamine
levels by commercial kit used according to the manufacturer’s
guidelines. Fructosamine kit was purchased from Labtest (Brazil).a Po0.05 compared to non-diabetic rats.
b Po0.05 compared to diabetic rats.2.9. Treatments
The PPAR-g agonist rosiglitazone (0.5 mg/kg) was adminis-
tered i.p. 3 day after diabetes induction, once a day during 18
consecutive days. Non-diabetic rats were treated daily with
rosiglitazone (0.5 mg/kg, i.p.), for 18 consecutive days, and were
used as a control group. In some experiments, diabetic animals
were pre-treated with the PPAR-g antagonist 2-chloro-5-nitro-
benzanilide (GW9662), 0.5 mg/kg i.p. 30 min before treatment
with rosiglitazone, once a day during 18 consecutive days. Non-
diabetic and diabetic rats were treated daily with GW9662
(0.5 mg/kg, i.p.), for 18 consecutive days, and were used as
controls. Untreated non-diabetic and diabetic rats received an
equal volume of vehicle (DMSO 0.05%, i.p.).2.10. Drugs
Alloxan monohydrate, o-phthaldialdehyde (OPT), paraformal-
dehyde, HBSS, dimethyl sulfoxide (DMSO) and toluidine blue dye
were purchased from Sigma Chemical Co (St. Louis, USA), murine
anti-DNP IgE mAb, dinitrophenylated bovine serum albumin
(DNP-BSA) and sucrose from Calbiochem (San Diego, USA), Percoll
from GE Healthcare (Uppsala, Sweden), rosiglitazone and
GW9662 from Cayman Chemicals (St. Louis, USA), Giemsa dye
from Merck (Darmstadt, Germany) and sodium heparin from
Roche (S~ao Paulo, Brazil). All solutions were freshly prepared
immediately before use.2.11. Statistical analysis
The data are reported as mean7standard error of the mean
(S.E.M.) and statistically analyzed by ANOVA followed by
Newman–Keuls-Student’s t test. Probability values (P) of 0.05 or
less were considered signiﬁcant.3. Results
3.1. Involvement of PPARg on alloxan-induced alterations in rats
Alloxan-diabetic rats presented a drastic reduction in the
plasma and mesenteric levels of 15d-PGJ2, a natural agonist of
PPARg, when compared to non-diabetic rats (Fig. 1). Moreover,
the injection of alloxan increased blood glucose and plasma
fructosamine, with a simultaneous decrease in body weight and
plasma insulin levels (Table 1), indicative of diabetic state. In
addition, there was a reduction in the mast cell population
present in the pleural cavity and mesenteric tissue of diabetic
rats in comparison with non-diabetic rats (Fig. 2). Administration
of rosiglitazone, a synthetic PPARg agonist (0.5 mg/kg, i.p.), to
diabetic rats led to partial, though signiﬁcant inhibition of the
increased blood glucose levels. However, the increased levels of
plasma fructosamine, reduced body weight and hypoinsulinemia
were not altered in rosiglitazone-treated diabetic rats (Table 1).
As shown in Fig. 1, rosiglitazone restored the number of mast cells
in the pleural cavity and mesenteric tissue of diabetic rats to
values close to those in non-diabetic untreated animals. Basal
mast cell population was not changed in the control (non-diabetic
untreated rats) after treatment with rosiglitazone.
We used a pharmacological approach to determine whether
the action of rosiglitazone on hyperglycemia and mastocytopenia
observed in diabetic rats was mediated by PPARg. The reduced
blood hyperglycemia and increased mast cell population in the
pleural cavity and mesenteric tissue of diabetic rats that rosigli-
tazone produced, were completely reversed when these animals
were treated with GW9662, a PPARg-speciﬁc antagonist. In the
non-diabetic and diabetic untreated rats, administration of
GW9662 did not affect the blood glucose levels, pleural or
mesenteric mast cell numbers (Table 2).
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Fig. 2. Effect of rosiglitazone on pleural (A) and mesenteric (B) mastocytopenia observed in diabetic rats. Three days after diabetes induction, rosiglitazone (0.5 mg/kg, i.p.)
was administered once a day for 18 consecutive days. Control animals were treated daily with rosiglitazone for 18 consecutive days. Untreated animals received an equal
amount of vehicle (DMSO 0.05%, i.p.). Data are expressed as mean7S.E.M. of 6 animals. This result is representative of two independent assays. þPo0.05 compared to
non-diabetic rats. *Po0.05 compared to diabetic rats untreated with rosiglitazone.
Table 2
Effect of PPARg antagonist GW9662 on the restoration of blood glucose and mast cell population induced by rosiglitazone in alloxan-diabetic rats.
Group Drug Glycemia (mmol/l) Mast cells
Pleural (x103)/site Mesenteric (x103)/mm2
Non-diabetic – 670.1 465723 8778
Rosiglitazone 670.3 498716 7070.7
GW9662 670.3 481720 7877
Diabetic – 3070.6a 316718a 4272a
Rosiglitazone 2670.8b 475716b 7272b
GW9662 2871 278717 4874
GW9662 plus Rosiglitazone 3171c 338735c 5172c
Diabetic rats were treated with rosiglitazone (0.5 mg/kg, i.p.) or GW-9662 (0.5 mg/kg, i.p.) and the analyses performed 21 day after diabetes induction. Untreated animals
received an equal amount of vehicle (DMSO 0.05%, i.p.). Values represent mean7S.E.M. of 6 animals.
a Po0.05.
b Po0.05.
c Po0.05 compared to non-diabetic, diabetic untreated with rosiglitazone and rosiglitazone-treated diabetic rats, respectively.
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Fig. 3. Effect of rosiglitazone on the suppression of histamine release by mast cells
from diabetic rats triggered with antigen in vitro. Peritoneal mast cells were
collected from non-diabetic or diabetic rats, treated or untreated with rosiglita-
zone. Three days after diabetes induction, rosiglitazone (0.5 mg/kg, i.p.) was
administered once a day for 18 consecutive days. Non-diabetic animals were
treated daily with rosiglitazone for 18 consecutive days. Untreated animals
received an equal amount of vehicle (DMSO 0.05%, i.p.). Data are expressed as
mean7S.E.M. of 3 animals. This result is representative of two independent
assays. þPo0.05 compared to non-stimulated cells. nPo0.05 compared to
stimulated cells. #Po0.05 compared to stimulated cells from diabetic animals
untreated with rosiglitazone.
R.C. Torres et al. / European Journal of Pharmacology 691 (2012) 261–2672643.2. Effect of rosiglitazone on refractoriness of mast cells isolated
from diabetic rats
Puriﬁed peritoneal mast cells stimulated with antigen in vitro
exhibited a marked increase in the levels of histamine release, an
effect clearly suppressed in mast cells recovered from diabetic
rats. Yet, when rosiglitazone (0.5 mg/kg, i.p.) was given to diabetic
rats, the hyporeactivity of mast cells to antigen in vitro was
reversed. Lower levels of histamine release after stimulation with
antigen in vitro was seen in the mast cells recovered from
rosiglitazone-treated non-diabetic rats when compared with
untreated non-diabetic rats. Basal histamine release in the mast
cells showed no change between the treated and non-treated or
the diabetic and non-diabetic groups (Fig. 3).
3.3. Effect of rosiglitazone on diabetes-induced apoptosis in mast cells
Conﬁrming previous data of Barreto et al. (2006), we found that
mast cells from diabetic rats exhibited higher rate of apoptotic cells
when compared to the mast cells from non-diabetic rats. Mast cells
from rosiglitazone-treated diabetic rats exhibited lower number of
TUNEL positive mast cells, indicating a lower rate of apoptosis as
compared with mast cells from untreated diabetic rats. There was no
difference seen in the mast cell apoptosis within the rosiglitazone
treated non-diabetic rats and the untreated non-diabetic rats (Fig. 4A
D). Quantitative data are seen in Fig. 4E.
3.4. Involvement of PPARg on the hypercorticolism noted in diabetic rats
As shown in Fig. 5, treatment with rosiglitazone signiﬁcantly
impaired the enhancement of plasma corticosterone levels ofdiabetic rats to values close to those in control animals. No
alteration of basal levels of corticosterone was observed in
control non-diabetic rats after treatment with rosiglitazone.
Pre-treatment with GW9662 completely reversed the effects
of rosiglitazone on hypercorticolism of diabetic rats. Compared
with the non-diabetic and diabetic untreated rats, administra-
tion of GW9662 did not affect the plasma corticosterone levels
(Fig. 5).
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Fig. 4. Effect of rosiglitazone on the increased apoptosis in mast cells from diabetic animals. Panels show photomicrographs of toluidine blue-stained mast cells, plus
TUNEL marking (arrows), from the peritoneal cavity of non-diabetic untreated (A), rosiglitazone-treated non-diabetic (B), diabetic untreated (C) and rosiglitazone-treated
diabetic (D) animals. Untreated animals received an equal amount of vehicle (DMSO 0.05%, i.p.). Panel E shows that rosiglitazone abolished the increased apoptosis in mast
cells from diabetic rats. Data are expressed as mean7SEM from 4 animals. This result is representative of two independent assays. þPo0.05 compared to mast cells from
non-diabetic animals. nPo0.05 compared to mast cells from diabetic animals untreated with rosiglitazone.
600
800
+ #
l)
Non-diabetic
Diabetic
400 *(ng
/m
l
200
Pl
as
m
a 
co
rt
ic
os
te
ro
ne
o
0
Rosiglitazone: - - - -+ + +
GW9662: - + - +- - +
Fig. 5. Role of PPARg on increased levels of plasma corticosterone observed in
diabetic rats. Three days after diabetes induction, rosiglitazone (0.5 mg/kg, i.p.)
and GW9662 (0.5 mg/kg, i.p.) were administered once a day for 18 consecutive
days. Control animals were treated daily with rosiglitazone or GW9662 for 18
consecutive days. Untreated animals received an equal amount of vehicle (DMSO
0.05%, i.p.). Data are expressed as mean7S.E.M. of at least 5 animals. This result is
representative of two independent assays. þPo0.05 compared to non-diabetic
rats. nPo0.05 compared to diabetic rats untreated with rosiglitazone. #Po0.05
compared to diabetic rats treated with rosiglitazone.
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In this study, we focused on the contribution of PPARg in the
reduction of mast cell number and reactivity in diabetic rats. We
found that treatment with rosiglitazone, a PPARg agonist,
restored basal pleural and mesenteric mast cell numbers in
diabetic rats and mast cell reactivity in vitro, correlating strongly
with a decreased level of apoptosis in mast cells. In addition,
rosiglitazone reduced plasma corticosterone levels in diabetic
rats, without interfering with hypoinsulinemia. Our ﬁndings
indicate that PPARg seems to have an important involvement in
the mast cell depletion and refractoriness in diabetic rats, with a
clear dependency on the reduced percentage of apoptotic mast
cells and plasma corticosterone levels.
Initially, we identiﬁed a signiﬁcant decrease in the plasma and
mesenteric levels of 15d-PGJ2 in diabetic rats when compared
with non-diabetic rats. 15d-PGJ2 is proposed as one of major
endogenous ligands for the g isoform of the PPARs (Forman et al.,
1997), which suggests that the signaling pathway 15d-PGJ2/
PPARg decreases in diabetes. Given as previously described that
R.C. Torres et al. / European Journal of Pharmacology 691 (2012) 261–267266there is a depletion in the number of the mast cell in the pleural
and peritoneal cavities as well as, mesentery, intestine and skin
tissues in diabetic animals (Carvalho V de et al., 2009; Carvalho
et al., 2011; de F Carvalho et al., 2008), and that here we observed
a systemic reduction of 15d-PGJ2 levels, most markedly in the
mesentery tissue, we proposed that the use of synthetic PPARg
activators could restore the mast cell number and reactivity in
alloxan-diabetic rats.
In this study we showed that alloxan-induced reduction in the
pleural and mesenteric mast cell population was abolished by
rosiglitazone, though the increase in the serum glucose levels was
only partially inhibited by the drug, indicating that mast cell
depletion under diabetic conditions seems to be at least partially
dependent on hyperglycemia. In addition, hypoinsulinemia in
diabetic rats was not affected by treatment with rosiglitazone,
suggesting that the effect of rosiglitazone on diabetes-induced
hyperglycemia and decrease of mast cell numbers seems to be
accounted for by factor(s) other than the drop in insulin levels.
The partial reduction of glycemia in rosiglitazone-treated diabetic
rats can be explained by the fact that PPARg activation improves
insulin sensitivity, a phenomenon that promotes glucose meta-
bolism without increasing insulin secretion (Ikeda et al., 1990).
We also showed that rosiglitazone failed to affect body weight
and plasma fructosamine levels in diabetic rats. This ﬁnding is
surprising because thiazolidinediones, including rosiglitazone, are
able to signiﬁcantly increase body weight by inducing adipogen-
esis and lipogenesis (Kusunoki et al., 2011; Yang et al., 2010) and
reduce advanced glycation end products in diabetics (Oz Gul
et al., 2010). One possible explanation is that we used a dose of
PPARg agonist approximately 40 times lower than those utilized
in these other studies.
Although thiazolidinediones are widely known as ligands for
PPARg, they may mediate receptor-independent effects (Biscetti
et al., 2009; Liu et al., 2005; Turturro et al., 2007). To understand
whether an increase in the number of pleural and mesenteric
mast cells and a decrease in the serum glucose levels by
rosiglitazone are PPARg-dependent in diabetic rats, we performed
experiments using a PPARg antagonist GW9662. Here, we showed
that the effects of rosiglitazone on hyperglycemia and mastocy-
topenia were completely abolished in rosiglitazone-treated dia-
betic rats that were pre-treated with GW9662, suggesting that
these phenomena are dependent on the PPARg activation by
rosiglitazone.
Moreover, we noted that the puriﬁed mast cells from diabetic
rats showed a decreased response following stimulation with
antigen in vitro when compared to those obtained from non-
diabetic rats. These ﬁndings are consistent with our previous
ﬁndings in which we demonstrated that mast cells from diabetic
animals are refractory to several inﬂammatory stimuli such as
antigen, bradykinin, substance P and compound 48/80 (Barreto
et al., 2004; Carvalho et al., 2011). Since the amount of histamine
stored in diabetic mast cell granules was shown not to be
different from that found in normal cells (Diaz et al., 1996), we
could infer that alloxan-induced diabetes promoted a decrease in
the reactivity of mast cells rather than their degranulation. In
another set of experiments, we noted that when mast cells were
isolated from rosiglitazone-treated diabetic rats, there was a
reversal of their responsiveness. However, mast cells recovered
from rosiglitazone-treated non-diabetic rats showed a decreased
response after antigen stimulation in vitro. Consistent with this
data, several studies showed that activation of PPARg attenuates
antigen-induced histamine and lipid mediator release, including
leukotriene B4 and Cys-leukotrienes (Sugiyama et al., 2000;
Yamashita et al., 2000). Treatment with rosiglitazone in vivo
restored mast cell degranulation, a phenomenon clearly asso-
ciated with the reduction of the apoptotic rate as attested by theTUNEL assay. It was previously reported that ligand-activated
PPARg controls apoptosis. Nevertheless, the literature remains
inconsistent and controversial, while some have provided experi-
mental evidence to support the anti-apoptotic actions of PPARg
agonists (Fuenzalida et al., 2007; Lin et al., 2006), others have
reported pro-apoptotic actions of these ligands (Lim et al., 2006;
Shiau et al., 2005). The reason for this duality of PPARg agonists is
unclear. Nonetheless, it is believed that PPARg agonists at
relatively low concentrations are anti-apoptotic, while at high
concentrations, they are pro-apoptotic (Fong et al., 2010).
We previously described that the reduction of mast cell
number and reactivity in diabetic rats was associated with a
hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis
with a consequent hypercortisolism (eSilva et al., 2009). It has
been demonstrated that the increased HPA activity in diabetic
rats can be normalized by insulin (Chan et al., 2002). In addition
to being insulin sensitizers, thiazolidinediones can suppress
adrenocorticotropic hormone (ACTH) and corticosterone secre-
tion in mice with murine corticotroph tumors and in patients
with Cushing’s disease (Ambrosi et al., 2004; Heaney et al., 2002).
In fact, it was previously demonstrated that PPARg agonists
inhibit ovarian steroidogenesis (Mitwally et al., 2002) and the
activity of steroidogenic enzymes in native microsomal environ-
ments (Arlt et al., 2001). We demonstrated here that rosiglitazone
showed the ability to inhibit the diabetes-induced hypercortico-
lism under conditions where basal levels of plasma glucocorti-
coids in non-diabetics were not modiﬁed, and this effect was
abolished with pre-treatment with GW9662. Thus, it can be
hypothesized that the effectiveness of PPARg to reverse mast cell
depletion and responsiveness in diabetic rats might be, at least
partially, dependent on its ability to inhibit the elevation in
glucocorticoid levels. In addition, since glucocorticoids have been
reported to have the ability to induce hyperglycemia, we can
speculate that the partial inhibition of alloxan-induced elevation
in the glucose levels by rosiglitazone could be associated with its
ability to suppress the hypercorticolism.
In summary, our results indicate that activation of PPARg by
rosiglitazone restored mast cell numbers and reactivity in dia-
betic rats, a phenomenon accompanied with the decrease in mast
cell apoptosis and hypercorticolism associated with diabetes.Acknowledgments
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